March 3, 2026Open Access

Targeting Colorectal Cancer Stem Cells Through Inhibition of the Fibroblast Growth Factor Receptor 4 Pathway with a Novel Antibody

Key Points

Successful identification of CSC-selective membrane antigens highlights potential therapeutic targets.
FGFR4 inhibition using the anti-FGFR4 3B6 monoclonal antibody reveals diagnostic and therapeutic promise.
The development of the 3B6 antibody specifically targets colorectal cancer stem cells effectively.
Implications for colorectal cancer therapy emphasize the need for targeting stem cell pathways in treatment strategies.

Abstract

This study successfully identified several CSC-selective membrane antigens that can become therapeutic targets in CRC. Among them, we focused on FGFR4 as a promising target and developed the anti-FGFR4 3B6 monoclonal antibody which offers potential for both diagnostic and therapeutic applications.

Connected Papers

Building similarity graph...

Analyzing shared references across papers

Discussion

Authors

Gessica Filocamo

Rome International School

Mariachiara Buccarelli

Istituto Superiore di Sanità

Armin Lahm

Institute of Bioinformatics

Journals

Cancers

Actions

Institutions

Istituti di Ricovero e Cura a Carattere Scientifico

Università Cattolica del Sacro Cuore

Istituto Superiore di Sanità

References and Citations

Connected Papers

Building similarity graph...

Analyzing shared references across papers

Targeting Colorectal Cancer Stem Cells Through Inhibition of the Fibroblast Growth Factor Receptor 4 Pathway with a Novel Antibody

Key Points

Abstract

Citation Network

Connected Papers

Discussion

Authors

Journals

Actions

Institutions

References and Citations

Citation Network

Connected Papers

Discussion

Cite this study

Also consider

Also consider